Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spectinomycin is an aminocyclitol antibiotic produced by *Streptomyces spectabilis*. It is primarily used for the treatment of gonorrhea caused by susceptible strains of *Neisseria gonorrhoeae*. Spectinomycin acts as a bacteriostatic agent, though it can be bactericidal at high concentrations. Its mechanism of action involves binding to the 30S subunit of the bacterial ribosome, specifically interacting with 16S rRNA helix 34, thereby inhibiting protein synthesis by blocking the translocation step. The drug is rapidly absorbed after intramuscular injection and excreted via glomerular filtration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spectinomycin.